anand Varadan serves as Executive Vice President, Chief Commercial Officer of the Company since April 22, 2020 and previously served as our Chief Commercial Officer from August 2015 to June 2016. Most recently, Mr. Varadan provided commercial and strategic consultancy services to the Company as well as a variety of other biotech companies and investors through his consulting firm, Ignition Insights, LLC, which he has operated since June 2016. From June 2018 to July 2019, Mr. Varadan served as Executive Vice President, Chief Commercial Officer of Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), an oncology-focused pharmaceutical company. From January 1999 to July 2015, he served in a progression of commercial leadership and general management roles at Amgen Inc. (NASDAQ: AMGN), a biopharmaceutical company, including Vice President, Inflammation and Nephrology Business Unit from April 2014 to July 2015 and Vice President/General Manager, Amgen Canada from September 2011 to April 2014. Prior to Amgen, Mr. Varadan was a brand manager at Procter and Gamble Company (NYSE: PG). Mr. Varadan received an M.B.A. from the Simon Business School at the University of Rochester and a B.A. in Zoology from The George Washington University.
As the Executive Vice President a Chief Commercial Officer of Chiasma Inc, the total compensation of anand Varadan at Chiasma Inc is $1,568,720. There are 1 executives at Chiasma Inc getting paid more, with Raj Kannan having the highest compensation of $6,413,280.
anand Varadan is 53, he's been the Executive Vice President a Chief Commercial Officer of Chiasma Inc since 2020. There are 7 older and 4 younger executives at Chiasma Inc. The oldest executive at Chiasma Inc is John Scarlett, 69, who is the Independent Director.
Anand's mailing address filed with the SEC is C/O PULMATRIX, INC., 99 HAYDEN AVE, , LEXINGTON, MA, 02421.
Over the last 9 years, insiders at Chiasma Inc have traded over $0 worth of Chiasma Inc stock and bought 324,855 units worth $2,372,906 . The most active insiders traders include Llp Abingworth, Ansbert Gadicke a John F Thero. On average, Chiasma Inc executives and independent directors trade stock every 85 days with the average trade being worth of $94,895. The most recent stock trade was executed by Roni Mamluk on 9 February 2021, trading 27,981 units of CHMA stock currently worth $51,765.
Chiasma is a commercial-stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. In June 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA, the first and only oral somatostatin analog approved by the FDA, is available for commercial sale. Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma.
Chiasma Inc executives and other stock owners filed with the SEC include: